Nucleotides

2'-O-Propargylcytidine is a novel nucleoside that has been modified from cytidine. It is designed to inhibit the activity of RNA polymerase and to be used in anticancer therapy. The synthesis of 2'-O-propargylcytidine has been achieved by modifying the nucleotide with propargylic chloride, which is then reacted with sodium cyanide. The resulting product is purified by column chromatography and recrystallization.
2'-O-Propargylcytidine is a phosphoramidite that can be used for DNA synthesis or as a monophosphate in RNA synthesis. This high purity product has a CAS number of 206552-85-4 and it can be used as an activator for ribonucleosides, such as adenosine, guanosine, uridine, cytidine, and thymidine.

8-azido-2-deoxyadenosine is an azide funcationalised nuceleoside

Inosine 5'-monophosphate disodium salt hydrate is a nucleotide that is synthesized from adenosine triphosphate in the energy metabolism of cells. It is used as an activator of signal pathways and as a potent inducer of metabolic enzymes. Inosine 5'-monophosphate disodium salt hydrate has been shown to induce bowel disease in mice with experimental colitis, suggesting its utility for treating inflammatory bowel disease. Inosine 5'-monophosphate disodium salt hydrate binds to the ATP-binding site of GTPase, stimulating the hydrolysis of ATP to ADP and phosphate. This reaction causes a conformational change in the enzyme's active site that increases the affinity for GTP by about 10-fold. The binding site is composed of two alpha helices sandwiching a central beta sheet and the catalytic residues are located at both ends of this beta sheet. Structural analysis has revealed that this drug interacts with

2',5'-Dideoxyuridine is a synthetic nucleoside analog derived from uridine, one of the four standard nucleosides found in RNA. It is chemically modified by the removal of hydroxyl (–OH) groups at the 2' and 5' positions of the sugar, altering its ability to participate in RNA or DNA chain formation.

Cytidine is a nucleoside that belongs to the group of pyrimidine nucleosides. It can be absorbed from the intestine and hydrolyzed to uridine by intestinal enzymes. Cytidine has been shown to inhibit angiogenesis in animal model systems and transfection experiments, as well as being genotoxic in vitro. Cytidine has also been shown to inhibit polymerase chain reactions (PCR) and enzyme activities, such as cytidine deaminase, which converts cytidine into uracil.

2'-Deoxy-5-hydroxycytidine is a nucleoside analog that is used to treat human immunodeficiency virus (HIV). It inhibits the synthesis of HIV by inhibiting the enzyme reverse transcriptase. This drug binds to DNA duplexes, and has been shown to be reactive with damaged DNA. The compound has been shown to inhibit viral replication in a model system, and also inhibits the polymerase chain reaction. 2'-Deoxy-5-hydroxycytidine may also have thermodynamic properties that are related to its potential for reactivity with oxidative DNA.
2'-Deoxy-5-hydroxycytidine is an analog of cytidine. It can be synthesized using solid phase synthesis on a resin support.

3'-Deoxyinosine is a nucleoside analog that is used in the treatment of leukemia, lymphoma, and AIDS-related Kaposi's sarcoma. The drug inhibits DNA synthesis by inhibiting enzymes such as ribonucleotide reductase, thymidylate synthase, and dihydrofolate reductase. 3'-Deoxyinosine has minimal toxicity and may be administered orally or intravenously. It has been shown to have an inhibitory effect on the growth of skin cancer cells and leishmania parasites in cell culture. This drug also lowers blood pressure by interfering with the synthesis of angiotensin II and may be useful for treating hypertension. The drug is synthetically prepared in a laboratory by chemists.